This is a preview of subscription content, log in via an institution to check access.
Reference
Smith B, et al. Is the Progression Free Survival Advantage of Concurrent Gemcitabine plus Cisplatin and Radiation followed by Adjuvant Gemcitabine and Cisplatin in Patients with Advanced Cervical Cancer Worth the Additional Cost? A Cost-Effectiveness Analysis. Gynecologic Oncology : 26 May 2013. Available from: URL: http://dx.doi.org/10.1016/j.ygyno.2013.05.024
Rights and permissions
About this article
Cite this article
Better cost-effective treatment needed for cervical cancer. PharmacoEcon Outcomes News 682, 6 (2013). https://doi.org/10.1007/s40274-013-0540-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0540-1